Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
Key facts
- Who runs it
- University Hospital, Lille
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 450 people, planned
- Started
- 25 Dec 2014
- Expected to end
- Sept 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- collection of liver biopsies collection of blood samples
- Record updated
- 22 May 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- group A: patients with acute alcoholic hepatitis
- Active alcohol abuse defined by DSM IV and excessive alcohol consumption prior to admission (> 60 g per day for men and> 40 g per day for women)
- Moderate elevation of transaminases (less than 500 U / L) with a typical ASAT / ALAT ratio of 2: 1
- Bilirubin> 50 mg / l
- Absence of autoimmune liver disease (ANA <1/80, AML <1/80, LKM1 neg, AAM neg)
- Absence of hepatitis B and C and HIV infection (negative anti-HIV antibodies, negative HBsAg, negative HCV PCR)
- Patients with other acute complications than alcoholic hepatitis may be included (eg, digestive hemorrhage, acute renal failure, infection, etc.)
- Because there is no validated noninvasive tool for the diagnosis of alcoholic hepatitis, histological confirmation is required in all patients (preferably by transjugular biopsy): alcoholic hepatitis will be diagnosed on the presence of the following histological characteristics: Hepatocellular lesions (ballooning, Mallory body)/ Inflammatory infiltrate with polymorphonuclear neutrophils
- group B1: patients with alcoholic cirrhosis
- Decompensated or non-decompensated alcoholic cirrhosis, defined according to the HAS guidelines, ie by a liver biopsy or a cluster of clinico-biological arguments (www.has-sante.fr)
- group B2: patients free from chronic liver disease
- Justification of blood and liver sampling for the management of a pathology other than chronic liver disease (eg liver metastasis of digestive cancer occurring on healthy liver)
Who cannot take part
- Patients with hepatocellular carcinoma of progressive non-hepatic cancer
- Presence of anti-HCV antibodies by positive PCR
- Presence of antibodies to HIV 1 +2
- Alcoholic liver disease
- Presence of anti-HCV antibodies by positive PCR
- Presence of antibodies to HIV 1 +2
- For groups A and B1:
- Presence of HBsAg
- Pregnancy
- for group B2:
- Presence of HBsAg
- Pregnancy
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this study is the comparison of the profile of the pro-inflammatory cytokines at the patients suffering from an alcoholic hepatitis to that of two groups witnesses: patients suffering from an alcoholic cirrhosis and unhurt patients of chronic liver disease
The 3 groups in the trial
- acute alcoholic hepatitisOther group
collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
Treatment: collection of liver biopsies collection of blood samples
- Alcoholic cirrhosisOther group
collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
Treatment: collection of liver biopsies collection of blood samples
- Without chronic liver diseaseOther group
collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
Treatment: collection of liver biopsies collection of blood samples
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT03773887, who can take part
- Record updated
- 22 May 2026